Innoblative’s SIRA RFA Electrosurgical Device Receives a Breakthrough Device Designation from the US FDA for Breast Cancer Treatment
- The company received a Breakthrough Device Designation (BDD) from the US FDA for its SIR RFA electrosurgical device to be used in patients with breast cancer undergoing BCS (lumpectomy)
- In order to produce a consistent thermal effect, the electrosurgical device uses radiofrequency ablation (RFA) through a spherical shape that circumferentially delivers RF energy to the whole cavity
- In multiple long-term clinical studies, RFA has depicted the potential to reduce reoperation & local recurrence in breast cancer treatment. Additionally, Innoblative expects to present the data based on which it received the BDD at the ASBrS 2023
Ref: PR Newswire | Image: Innoblative
Related News:- Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) Receives the MHLW’s Approval as the First HER2 Directed Therapy for HER2 Low Metastatic Breast Cancer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].